Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Translating amyotrophic lateral sclerosis genes into drug development leads

Although clear genetic connections to ALS were first established three decades ago, there has been negligible progress in the development of disease-modifying treatments for this disease. Despite tremendous unmet need, industry has often been largely baffled by a disease seemingly designed to thwart current effective drug development approaches. In the largest genetic study of ALS to date, van Rheenen and colleagues use sophisticated analyses to gain novel insights into its pathogenesis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ALS-associated genes and approved drugs.


  1. van Rheenen, W. et al. Nat. Genet. (2021).

  2. Oakes, J. A. et al. Mol. Brain 10, 5 (2017).

    Article  Google Scholar 

  3. Kiernan, M. C. et al. Nat. Rev. Neurol. 17, 104–118 (2021).

    Article  Google Scholar 

  4. Phillips, T. et al. Curr. Protoc. Pharmacol. 69, 5.67.1–5.67.21 (2015).

    Article  Google Scholar 

  5. Richard, J. et al. Brain Res. 1607, 15–25 (2015).

    Article  CAS  Google Scholar 

  6. Lebedeva, I. V. et al. Cell Death Dis. 12, 770 (2021).

    Article  CAS  Google Scholar 

  7. Segeritz, C. J. et al. Hepatol. 69, 49–64 (2018).

    Article  Google Scholar 

  8. Prilutsky, D. et al. Trends Mol. Med. 20, 91–104 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Sunil Sahdeo or David B. Goldstein.

Ethics declarations

Competing interests

S.S. and D.B.G. are both employees of Actio Biosciences, a precision medicine biotechnology company. D.B.G. is a co-founder of Praxis Precision Medicines.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sahdeo, S., Goldstein, D.B. Translating amyotrophic lateral sclerosis genes into drug development leads. Nat Genet 53, 1624–1626 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing